Biomarker ID | 1618 |
PMID | 31035590 |
Year | 2019 |
Biomarker | IL4R [SNP: rs3024586; A vs G] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.56 (95% CI: 1.36–4.80) |
Effect on Pathways | Pathways include: Inflammatory response pathway, Selective expression of chemokine receptors during T-cell polarization, Th1/Th2 differentiation pathway, p73 transcription factor network, Hematopoietic cell lineage |
Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | 418 patients in the training cohort (80 experiencing Biochemical Recurrence) and 131 patients in the validation cohort (28 experiencing Biochemical Recurrence) were chosen for the study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.003 |
Method Used | Allele specific PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |